Translational Partnership Development Lead (NCI)
The Frederick National Laboratory for Cancer Research (FNLCR) is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc on behalf of the National Cancer Institute (NCI). The staff of FNLCR support the NCI’s mission in the fight against cancer and HIV/AIDS. Currently we are seeking a Translational Partnership Development Lead (TPDL) who will work closely with the Office of Translation Resources (OTR) within the Office of the Director (OD) of NCI’s Center for Cancer Research (CCR) to facilitate the successful translation of CCR’s basic and preclinical research advances into new therapeutics and diagnostics. The TPDL with be strategically aligned within FNLCR’s Partnership Development Office (PDO), to maximally leverage the critical mass of expertise available within the PDO.
CCR comprises the basic and clinical components of the NCI’s Intramural Research Program (IRP) and consists of ~230 basic and clinical Investigators located at either the NIH main campus or the NCI-Frederick campus. CCR Investigators are focused primarily on cancer and HIV/AIDS, with special emphasis on the most challenging and important high-risk/high-reward problems driving the fields. (See https://ccr.cancer.gov/ for a full delineation of the CCR Investigators and research activities.) The process of developing research findings into new clinical applications is high risk, complex, variable, and requires multiple areas of expertise seldom available within the confines of a single Investigator’s laboratory. To accelerate this process, OTR serves as a unifying force within CCR for all aspects of translational activities required to achieve success and maintain timely progress. A key aspect of OTR’s function is to develop and strengthen essential communications and collaborations within NIH, with extramural partners and with industry to bring together experts in chemistry, human subjects research, intellectual property, mouse study design, pharmacokinetics (PK), drug screening, industrial project management and other areas needed to facilitate rapid translation.
Currently, FNLCR is seeking an expert who can work across organizational boundaries to catalyze these interactions with the primary objective to develop and enable strategies that will facilitate the identification of partners who can collaborate with CCR Investigators. The TPDL will work with the partners and NCI to facilitate the swift and effective translation of pre-clinical discoveries with high potential toward clinical application. A critical part of the TPDL function will be to strengthen interactions among groups with strong translational interests located at NCI-Frederick, including the Molecular Targets Laboratory (MTL), and the NIH main campus, including the National Center for Advancing Translational Science (NCATS).
- Advise Principal Investigators and senior leadership on project-based and organizational/translational strategies for discoveries
- Enable partnerships and strengthen communications/collaborations within and outside of NIH with biotech industry and groups with strong translational interests/expertise. This includes continuing and strengthening the close collaboration with the Molecular Targets Laboratory (MTL) in Frederick as well as increasing interactions with groups that can facilitate drug development and translational work such as those at NCATS, the NCI’s Division of Cancer Treatment and Diagnosis (DCTD) and with current and potential industry partners
- Facilitate outreach to biotech/pharma to develop partnerships furthering translational research projects that may lead to licensing or other agreements
- Create outreach opportunities aimed at engaging PIs with potential drug development projects and providing guidance through the translational pipeline
- Identify strategic improvements in CCR technology and drug development process and infrastructure
To be considered for this position, you must minimally meet the knowledge, skills, and abilities listed below
- Ph.D. and/or M.D. from an accredited college/university according to the Council for Higher Education Accreditation (CHEA) in a health science or related biomedical field, applicable to cancer research. Foreign degrees must be evaluated for U.S. equivalency
- Must have at least five (5) years of experience in biotechnology and/or drug development and broad knowledge of translational strategies applicable to cancer research
- The ideal candidate will have extensive diagnostic and therapeutic development experience in industry i.e. drugs, imaging technologies, cellular therapies and instrumentation and the demonstrated ability to work effectively with Investigators
- Broad knowledge and skill in commercial biomedical research technology development involved in using the applied knowledge of biology to advance biomedical research by developing products for human diseases and conditions, particularly cancer
- Expert knowledge of industry drug development process, structure and milieu
- In-depth knowledge of the product and the development process. Knowledge of the design, development and enhancement of current biomedical products and processes including new-product development, process optimization and process validation. Thorough understanding of production processes and generally accepted industry practices
- Mastery of the methods and principles of medical and/or scientific research, as would typically be acquired through an advanced degree and additional training and professional experience in a health sciences, medical, or allied health field, such as biology, biological sciences, microbiology, pharmacology, toxicology, public health, medicine, or chemistry. Such knowledge is used to review and advise the research community on opportunities and review requirements and instruments to satisfy program objectives related to drug development, technology transfer, protection of intellectual property, and licensing.
- Sound knowledge of molecular biology concepts
- Must be able to obtain and maintain a security clearance
Candidates with these desired skills will be given preferential consideration:
- Ability to identify translational opportunities within the CCR research portfolio
- Ability to develop partnerships across CCR research teams with extramural and industry collaborators for the purpose of developing preclinical discoveries in to clinical application
- Advanced knowledge of and skill in drug development and industrial pharmaceutical toxicology and safety assessment drug development
- Demonstrated skill in the design, coordination, analysis and documentation of preclinical studies
- Knowledge of the structure and functions of research institutions and the translation of research findings into technology and marketable health products